Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Revenue (2020 - 2025)

Lyell Immunopharma's Revenue history spans 6 years, with the latest figure at $15000.0 for Q3 2025.

  • For Q3 2025, Revenue fell 55.88% year-over-year to $15000.0; the TTM value through Sep 2025 reached $41000.0, down 34.92%, while the annual FY2024 figure was $61000.0, 53.08% down from the prior year.
  • Revenue for Q3 2025 was $15000.0 at Lyell Immunopharma, up from $8000.0 in the prior quarter.
  • Across five years, Revenue topped out at $48.4 million in Q4 2022 and bottomed at $3000.0 in Q3 2022.
  • The 5-year median for Revenue is $27000.0 (2023), against an average of $5.0 million.
  • The largest annual shift saw Revenue surged 1614.6% in 2022 before it plummeted 99.97% in 2023.
  • A 5-year view of Revenue shows it stood at $2.8 million in 2021, then soared by 1614.6% to $48.4 million in 2022, then tumbled by 99.97% to $13000.0 in 2023, then dropped by 15.38% to $11000.0 in 2024, then surged by 36.36% to $15000.0 in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Revenue are $15000.0 (Q3 2025), $8000.0 (Q2 2025), and $7000.0 (Q1 2025).